| Treatment group (n = 11) | Control (n = 5) | P value |
Age | 74 | 58 | 0.33 |
Sex (male) | 5 | 4 | 0.44 |
Disease duration (years) | 8.5 | 5.8 | 0.22 |
Height (cm) | 154 | 166 | 0.01 |
Weight (kg) | 44 | 61 | 0.001 |
BMI | 18.8 | 21.1 | 0.009 |
Hoehn and Yahr stage (on) | 3.5 | 2.4 | 0.019 |
UPDRS I | 5.4 | 1.8 | 0.003 |
UPDRS II | 15.7 | 6.4 | 0.001 |
UPDRS III | 25.5 | 9.8 | 0.003 |
UPDRS IV | 2.5 | 1 | 0.15 |
MIBG early | 1.66 | 1.60 | 0.41 |
MIBG delay | 1.43 | 1.38 | 0.80 |
Medication |
|
|
|
Carbidopa-Levodopa (mg) | 482 | 320 |
|
Entacapone (mg) | 450 (n = 2) |
|
|
Pramipexole hydrochloride hydrate (mg) | 1.5 (n = 3) | 1.6 (n = 4) |
|
Ropinirole hydrochloride (mg) | 12.2 (n = 6) |
|
|
Selegiline hydrochloride (mg) | 4.2 (n = 2) | 5 (n = 1) |
|
Amantadine hydrochloride (mg) | 130 (n = 2) | 100 (n = 1) |
|
Zonisamide (mg) | 25 (n = 3) |
|
|